復星醫藥(600196.SH):控股子公司與紐科簽訂許可協議
格隆匯7月28日丨復星醫藥(600196.SH)公佈,公司控股子公司復星醫藥產業與紐科簽訂《許可協議》,根據約定,復星醫藥產業獲紐科授予其在研的以AR1001分子作爲其活性成分的藥物於約定許可區域(即中國境內及港澳地區)及領域(即用於阿爾茨海默病及其他神經系統疾病的診斷、預防和治療)的開發、註冊、生產及商業化權利。根據約定,復星醫藥產業將就本次許可向紐科支付至多人民幣15,000萬元(包括首付款、監管里程碑付款),具體包括:①首付款人民幣4,000萬元;②根據許可產品於許可區域的註冊上市進展,支付至多人民幣11,000萬元的監管里程碑款項。
AR1001是一款擬用於延緩阿爾茨海默病(AD)疾病進程的小分子口服藥物,具有強效、高選擇性抑制磷酸二酯酶-5(PDE-5)的作用。該在研藥物由紐科自上遊許可方AriBioCO.,Ltd.許可引進後進行後續開發。截至本公告日期,許可產品用於治療早期阿爾茨海默病的全球多中心(包括中國境內)III期臨牀試驗正在進行中。已開展的臨牀前研究顯示,AR1001可清除阿爾茨海默病相關的澱粉樣斑塊並抑制Tau蛋白的異常磷酸化,同時抑制炎性反應,並提供神經保護作用。截至目前的臨牀試驗表明,AR1001具有良好的安全性特徵和血腦屏障透過性,對早期AD患者(輕度認知障礙至輕度癡呆)有潛在治療效果。截至本公告日期,全球範圍內尚無同靶點用於治療阿爾茨海默病藥物獲批上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.